We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Bio-Rad Launches Synthetic Negative and HAI Negative Run Controls

By LabMedica International staff writers
Posted on 08 Jul 2022
Print article
Image: Synthetic negative and HAI negative run controls (Photo courtesy of Bio-Rad)
Image: Synthetic negative and HAI negative run controls (Photo courtesy of Bio-Rad)

Bio-Rad Laboratories (Hercules, CA, USA) has expanded its molecular offering of quality controls with the launch of two new Exact Diagnostics products: Synthetic Negative Run Control, which complements the Tick-borne, Meningitis/Encephalitis and Sexually-Transmitted Infections products; and HAI Negative Run Control, which complements the Hospital-Associated Infections products. Both are external quality controls designed to be used with molecular assays to monitor their intra- and inter-run performance. These products may also be used for dilution or spike-in purposes such as assay validation and verification.

The Exact Diagnostics Synthetic Negative Run Control is screened negative for nine targets: Anaplasma phagocytophilum, Babesia microti, Bartonella quintana, Borrelia burgdorferi, Ehrlichia chaffeensis, Enterovirus (EV) Coxsackievirus A9, Herpes Simplex Virus-1 (HSV-1), Herpes Simplex Virus-2 (HSV-2), and Varicella Zoster Virus (VZV).The Exact Diagnostics HAI Negative Run Control is screened negative for 3 targets: Clostridium (Clostridioides) difficile, Methicillin-resistant Staphylococcus aureus (MRSA), and Methicillin-susceptible Staphylococcus aureus (MSSA).

These products enable laboratories to capture run-to-run, day-to-day, instrument-to-instrument, operator-to-operator, and lot-to-lot variations of their molecular assays. They can also be used to train laboratory operators and evaluate proficiency. Another application is the spike-in and dilution of positive specimens or analyte-containing materials for assay validation and verification. Both products are designed to save laboratories the time and costs associated with the labor-intensive screening, qualification, manufacturing and maintenance of clinical specimens that would otherwise be used as controls.

Related Links:
Bio-Rad Laboratories 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.